Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis

Thierry Bourguignon; Anne Bernard; Laurent Fauchier

doi:10.1055/s-0038-1641167

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(05): 945-947
DOI: 10.1055/s-0038-1641167

Letter to the Editor

Schattauer GmbH Stuttgart

Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis

Authors

Thierry Bourguignon

¹Department of Cardiac Surgery, Centre Hospitalier Regional Universitaire de Tours, Tours, France
Anne Bernard

²Department of Cardiology, Centre Hospitalier Regional Universitaire de Tours, Tours, France
Laurent Fauchier

²Department of Cardiology, Centre Hospitalier Regional Universitaire de Tours, Tours, France

Abstract

Full Text

References

References
1 Whitlock RP, Eikelboom JW. Prevention of thromboembolic events after bioprosthetic aortic valve replacement: what is the optimal antithrombotic strategy?. J Am Coll Cardiol 2012; 60 (11) 978-980
2 Heras M, Chesebro JH, Fuster V. , et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25 (05) 1111-1119
3 Orszulak TA, Schaff HV, Mullany CJ. , et al. Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. Ann Thorac Surg 1995; 59 (02) 462-468
4 Nishimura RA, Otto CM, Bonow RO. , et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70 (02) 252-289
5 Baumgartner H, Falk V, Bax JJ. , et al; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36) 2739-2791
6 Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007; 16 (06) 667-671
7 Aramendi JI, Mestres CA, Martinez-León J, Campos V, Muñoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005; 27 (05) 854-860
8 Colli A, Verhoye JP, Heijmen R. , et al; ACTION Registry Investigators. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008; 33 (04) 531-536
9 Akins CW, Miller DC, Turina MI. , et al; STS; AATS; EACTS. Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg 2008; 85 (04) 1490-1495
10 Filsoufi F, Rahmanian PB, Castillo JG, Bronster D, Adams DH. Incidence, imaging analysis, and early and late outcomes of stroke after cardiac valve operation. Am J Cardiol 2008; 101 (10) 1472-1478
11 Li Y, Walicki D, Mathiesen C. , et al. Strokes after cardiac surgery and relationship to carotid stenosis. Arch Neurol 2009; 66 (09) 1091-1096
12 Lip GYH, Collet JP, Caterina R. , et al; ESC Scientific Document Group. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2017; 19 (11) 1757-1758